Antares pharma inc.

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …Dec 2, 2023 · Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million. Jul 21, 2020 · Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...Jan 18, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Apr 14, 2022 · Credit: Arek Socha from Pixabay. Halozyme Therapeutics has signed a definitive agreement for the acquisition of all of the outstanding shares of Antares Pharma in a deal valued at nearly $960m or $5.60 for each share, in cash. A speciality pharmaceutical firm, Antares focuses on developing pharmaceutical products and technologies to address ...

Antares Pharma Description. Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products ...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...Dec 2, 2023 · Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate of $48.52 million. Jan 25, 2022 · Antares Pharma Inc. Serghei Lungu v. Antares Pharma Inc, No. 21-1624 (3d Cir. 2022) Annotate this Case. Download PDF. Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes. This site is protected by reCAPTCHA and the ... Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Drug Delivery Devices market - The market share is expected to increase by USD 77.26 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 6.28%. Dental Delivery Systems market - The market share has the potential to grow by USD 100.32 million during 2019-2023. The growth momentum will accelerate throughout ...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

View Antares Pharma, Inc. Marketing Contacts, Executives, Media Spend, Marketing Technologies and Brands. Open doors with marketers, their agencies and the ...Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results. Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...On April 12, 2022, Halozyme Therapeutics, Inc. (the “Buyer”, “Halozyme”, “Parent”, “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Antares Pharma, Inc., a Delaware corporation (the “Seller” or “Antares”), and Atlas Merger Sub, Inc. (“Merger Sub” or the “Acquirer”), a Delaware corporation and wholly owned …using Antares auto injector technology •~75% of all commercial lives covered • 18 Orange Book listed patents extending to 2038 •FY 2021 revenue of $62.2M, up 34% year-over-year XYOSTED® TLANDO™ •Oral testosterone replacement therapy (TRT) •Granted FDA approval on March 28, 2022 and commercially launched in June 2022 •2X/daily ...

Overview. Company Description: Antares Pharma understands antagonism towards needles. The company develops needle-free systems for administering injectable drugs. …SAN DIEGO, May 24, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the successful completion of its acquisition of Antares Pharma, Inc. (“Antares”). The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one minute after 11:59 p.m., Eastern Time, on Monday, May ...Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Our multi-use, disposable pen injector complements our portfolio of single-use pressure assisted auto injector devices. The disposable pen injector device is designed to deliver drugs by injection through needles from multi-dose cartridges. Our disposable pen injector is designed for chronic conditions such as diabetes, which require daily ...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma Inc (NASDAQ:ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ:HALO) for $5.60 per share in cash, valuing ...

Antares Pharma, Inc. Website. Get a D&B Hoovers Free Trial. Overview Company Description: Antares Pharma understands antagonism towards needles. The company develops needle-free systems for administering injectable drugs. Its Medi-Jector Vision system, for instance, injects a thin, high-pressure stream of liquid, eliminating the need …The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.Antares Pharma, Inc.: Otrexup is a folate analog metabolic inhibitor indicated for the: Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis...EWING - Antares Pharma, Inc. (NASDAQ: ATRS) ('the Company'), a pharmaceutical technology company, today announced that it entered into an exclusive license agreement with Ferring Pharmaceuticals ('Ferring'), a research-driven, specialty biopharmaceutical group, for the marketed product NOCDURNA (desmopressin …Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself …Antares Pharma Inc., Glide Pharmaceutical Technologies Ltd., Injex Pharma AG, Pharmajet, In .are some of the major players in the global market. Related Reports Limb Prosthetics Market

Plaintiff–Appellant Antares Pharma, Inc. (“Antares”) appeals from a decision of the United States District Court for the District of Delaware denying Antares' motion for preliminary injunction. Antares seeks to enjoin alleged infringement of claims 31, 34, 35, and 37 of a reissue patent, RE44, 846 (“the '846 patent”).

Exhibit 99.1 . Halozyme Completes Antares Pharma Acquisition . SAN DIEGO, May 24, 2022 — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced the successful completion of its acquisition of Antares Pharma, Inc. (“Antares”).. The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at …

Antares Pharma, Inc. (NASDAQ: ATRS)’s sale to Halozyme Therapeutics, Inc. for $5.60 per share in cash. If you are an Antares Pharma shareholder, ...A suit was filed on Wednesday in the Southern District of New York by investor Shiva Stein against defendants Antares Pharma, Inc., as well as the company’s board of directors. The complaint for ...Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients.Abstract. Medi-Ject Corporation (now Antares Pharma, Inc.) has been providing delivery devices for the needle-free administration of insulin for over 25 years. This study was one of the final steps in the development and premarket evaluation of Medi-Ject's newest needle-free system, the Medi-Jector Vision. This study was conducted to evaluate ... Delaware . 1-32302 . 41-1350192 (State or other jurisdiction. of incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...SALT LAKE CITY - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States.TLANDO is an oral testosterone product for …Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The companys injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA ...Jan 12, 2022 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Antares Pharma, Inc., a leader in self-injection drug delivery technology, announced the latest advancement in its proprietary line of VIBEX(TM) ...Follow. EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug ...Get the latest Antares Pharma Inc. (ATRS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ...

EWING, NJ, March 3, 2022 – Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net ...Antares Pharma, Inc. (Antares or 'the company') is a drug device company that develops and markets self-injection pharmaceutical products and technologies. The company develops these products with its partners and is designed to provide functional and commercial advantages, such as reduced side effects, improved safety and efficacy and …Aug 5, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... Instagram:https://instagram. best mortgage lenders missourirobinhood vs acornsbest platform for otc stockszurich insurance group ag Antares Pharma, Inc. (Amex:AIS) today announced an agreement with Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) to provide its needle-free injection system exclusively for use with a currently unnamed product in the U.S. Under the terms of the agreement, Teva will purchase all of its requirements for the injection system from …Abstract. Medi-Ject Corporation (now Antares Pharma, Inc.) has been providing delivery devices for the needle-free administration of insulin for over 25 years. This study was one of the final steps in the development and premarket evaluation of Medi-Ject's newest needle-free system, the Medi-Jector Vision. This study was conducted to evaluate ... archer daniels midland stock price todayhca holdings stock Antares Pharma Inc. announced that Ferring Pharmaceuticals Inc. has received U.S. Food and Drug Administration approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as ZOMACTON (somatropin [rDNA origin]) for injection, and the needle-free delivery system to be … spyg etf Symbol Techs., Inc. v. Lemelson Med., 277 F.3d 1361, 1366 (Fed. Cir. 2002). 7 12 ANTARES PHARMA INC. v. MEDAC PHARMA INC. different from the 1870 Act with regard to claiming, reissue, and the role of the PTO,” and that “[s]uch minor differences as exist between those provisions in the 1870 and the 1952 Acts have no bearing on [our …Antares Pharma Inc. Serghei Lungu v. Antares Pharma Inc, No. 21-1624 (3d Cir. 2022) Annotate this Case. Download PDF. Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes. This site is protected by reCAPTCHA and the ...“At one minute following 11:59 p.m., Eastern Time, on May 23, 2022, the Offer expired. Equiniti Trust Company, the depository and paying agent for the Offer, advised Purchaser that, as of the expiration of the Offer, a total of 139,371,158 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 81.56% of …